GOSSAMER BIO, INC. Long-Term Debt
GOSSAMER BIO, INC. (GOSS) had Long-Term Debt of $0 as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2025-03-13
- 2024-12-31: Long-term Debt, Excluding Current Maturities $0.00.
- 2024-09-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2024-06-30: Long-term Debt, Excluding Current Maturities $0.00.
- 2024-03-31: Long-term Debt, Excluding Current Maturities $0.00.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 |
| 2023-12-31 | $814.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $3.63M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $6.44M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $9.22M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $11.99M 10-K · filed 2024-03-05 |
| 2022-09-30 | $14.83M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $17.64M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $29.17M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $29.08M 10-K · filed 2023-03-17 |
| 2021-09-30 | $28.99M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $28.91M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $28.82M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $28.74M 10-K · filed 2022-03-03 |
| 2020-09-30 | $28.66M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $28.64M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $28.55M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $28.46M 10-K · filed 2021-02-26 |
| 2019-09-30 | $28.37M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $28.28M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |